EC approves Keytruda for first-line NSCLC regardless of PD-L1 expression

Merck & Co. said the European Commission approved Keytruda pembrolizumab plus carboplatin and either paclitaxel or Abraxane nab-paclitaxel as first-line treatment of metastatic, squamous non-small cell lung cancer regardless of PD-L1 expression.

Merck & Co. Inc. (NYSE:MRK) said the approval was based on data from the Phase III KEYNOTE-407 trial, in which Keytruda plus chemotherapy met the primary endpoints of improving progression-free survival (PFS) and overall survival (OS) vs. chemotherapy alone (see "Phase III Squamous NSCLC Survival Readouts at ASCO for Keytruda, Tecentriq")...